Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

NewAmsterdam Pharma (NAMS) Shares Outstanding (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Shares Outstanding for 4 consecutive years, with $114.4 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 5.86% to $114.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $114.4 million through Dec 2025, up 5.86% year-over-year, with the annual reading at $114.4 million for FY2025, 5.86% up from the prior year.
  • Shares Outstanding hit $114.4 million in Q4 2025 for NewAmsterdam Pharma, up from $113.2 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $114.4 million in Q4 2025 to a low of $81.8 million in Q1 2023.
  • Historically, Shares Outstanding has averaged $95.7 million across 4 years, with a median of $90.0 million in 2024.
  • Biggest five-year swings in Shares Outstanding: decreased 0.89% in 2023 and later skyrocketed 31.04% in 2024.
  • Year by year, Shares Outstanding stood at $83.2 million in 2022, then fell by 0.89% to $82.5 million in 2023, then soared by 31.04% to $108.1 million in 2024, then increased by 5.86% to $114.4 million in 2025.
  • Business Quant data shows Shares Outstanding for NAMS at $114.4 million in Q4 2025, $113.2 million in Q3 2025, and $112.5 million in Q2 2025.